John Sensintaffar

4.9k total citations · 2 hit papers
29 papers, 2.8k citations indexed

About

John Sensintaffar is a scholar working on Molecular Biology, Immunology and Computational Theory and Mathematics. According to data from OpenAlex, John Sensintaffar has authored 29 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 7 papers in Immunology and 5 papers in Computational Theory and Mathematics. Recurrent topics in John Sensintaffar's work include Heat shock proteins research (8 papers), Computational Drug Discovery Methods (5 papers) and Cell death mechanisms and regulation (4 papers). John Sensintaffar is often cited by papers focused on Heat shock proteins research (8 papers), Computational Drug Discovery Methods (5 papers) and Cell death mechanisms and regulation (4 papers). John Sensintaffar collaborates with scholars based in United States, Austria and Germany. John Sensintaffar's co-authors include Marcus F. Boehm, Francis Burrows, Adeela Kamal, Lin Zhang, Lawrence C. Fritz, Otoniel Martı́nez-Maza, Joanna M. Watson, Jonathan S. Berek, Jeffrey H. Hager and Nhin Lu and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

John Sensintaffar

28 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors

2003 1.1k citations Adeela Kamal, John Sensintaffar et al. Nature profile →
A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509

2013 455 citations James D. Joseph, Nhin Lu et al. Cancer Discovery profile →

Peers

Countries citing papers authored by John Sensintaffar

Since Specialization

Citations

This map shows the geographic impact of John Sensintaffar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Sensintaffar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Sensintaffar more than expected).

Fields of papers citing papers by John Sensintaffar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Sensintaffar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Sensintaffar. The network helps show where John Sensintaffar may publish in the future.

Co-authorship network of co-authors of John Sensintaffar

This figure shows the co-authorship network connecting the top 25 collaborators of John Sensintaffar. A scholar is included among the top collaborators of John Sensintaffar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Sensintaffar. John Sensintaffar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Discovery of Fragment-Based Inhibitors of SARS-CoV-2 PL ^Pro 2026 ·Journal of Medicinal Chemistry ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), D. Schultz, (unknown), (unknown), (unknown), (unknown), Kangsa Amporndanai, John Sensintaffar, Jason Phan, (unknown), Mark R. Denison, (unknown), Stephen W. Fesik	0
2	Structure-Based Discovery of Potent, Orally Bioavailable Benzoxazepinone-Based WD Repeat Domain 5 Inhibitors 2023 ·Journal of Medicinal Chemistry ·(unknown), (unknown), Jianhua Tian, Changho Han, Kenneth M. Meyers, Jiqing Sai, (unknown), (unknown), (unknown), John Sensintaffar, Bin Zhao, Kangsa Amporndanai, William Moore, Gordon M. Stott, William P. Tansey, Taekyu Lee, Stephen W. Fesik	7
3	A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia 2018 ·Cancer Discovery ·Haley E. Ramsey, Melissa A. Fischer, Taekyu Lee, Agnieszka E. Gorska, Maria P. Arrate, Londa Fuller, Kelli L. Boyd, Stephen A. Strickland, John Sensintaffar, Leah J. Hogdal, Gregory D. Ayers, Edward T. Olejniczak, Stephen W. Fesik, Michael R. Savona	254
4	Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograft 2018 ·Bioorganic & Medicinal Chemistry Letters ·Steven P. Govek, Céline Bonnefous, (unknown), Johnny Nagasawa, Mehmet Kahraman, Andiliy Lai, Karensa Douglas, Anna Aparicio, Beatrice Darimont, (unknown), James D. Joseph, Joshua Kaufman, Kyoung‐Jin Lee, Nhin Lu, Michael Moon, Rene Prudente, John Sensintaffar, Peter J. Rix, Jeffrey H. Hager, Nicholas D. Smith	7
5	BAX-BAK heterodimer as a pharmacodynamic biomarker of on-target drug action of Mcl-1 inhibitors to evaluate in-vivo effectiveness. 2018 ·Journal of Clinical Oncology ·Apurva K. Srivastava, Jeevan Prasaad Govindharajulu, Melinda G. Hollingshead, William Moore, (unknown), (unknown), Taekyu Lee, Edward T. Olejniczak, John Sensintaffar, (unknown), Ralph E. Parchment, James H. Doroshow, Stephen W. Fesik	2
6	Structure of a Myeloid cell leukemia-1 (Mcl-1) inhibitor bound to drug site 3 of Human Serum Albumin 2017 ·Bioorganic & Medicinal Chemistry ·Bin Zhao, John Sensintaffar, Zhiguo Bian, Johannes Belmar, Taekyu Lee, Edward T. Olejniczak, Stephen W. Fesik	17
7	Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods 2016 ·Journal of Medicinal Chemistry ·Nicholas F. Pelz, Zhiguo Bian, Bin Zhao, Subrata Shaw, James C. Tarr, Johannes Belmar, (unknown), DeMarco V. Camper, Craig M. Goodwin, Allison L. Arnold, John Sensintaffar, Anders Friberg, Olivia W. Rossanese, Taekyu Lee, Edward T. Olejniczak, Stephen W. Fesik	108
8	Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft 2015 ·Bioorganic & Medicinal Chemistry Letters ·Steven P. Govek, Johnny Nagasawa, Karensa Douglas, Andiliy Lai, Mehmet Kahraman, Céline Bonnefous, Anna Aparicio, Beatrice Darimont, (unknown), James D. Joseph, Joshua Kaufman, Kyoung‐Jin Lee, Nhin Lu, Michael Moon, Rene Prudente, John Sensintaffar, Peter J. Rix, Jeffrey H. Hager, Nicholas D. Smith	36
9	Abstract 4757: A novel class of selective estrogen receptors degraders regresses tumors in pre-clinical models of endocrine-resistant breast cancer 2014 ·Cancer Research ·James D. Joseph, Beatrice Darimont, Steven P. Govek, Dan Brigham, Jing Qian, John Sensintaffar, Gang Shao, Anna Aparicio, Mehmet Kahraman, Andiliy Lai, Kyoung‐Jin Lee, Nhin Lu, Johnny Nagasawa, Michael Moon, Peter J. Rix, (unknown), (unknown)	1
10	A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509 breakdown → 2013 ·Cancer Discovery ·James D. Joseph, Nhin Lu, Jing Qian, John Sensintaffar, Gang Shao, Dan Brigham, (unknown), Edna Chow Maneval, Isan Chen, Beatrice Darimont, Jeffrey H. Hager	455
11	XIAP is not required for human tumor cell survival in the absence of an exogenous death signal 2010 ·BMC Cancer ·John Sensintaffar, Fiona L. Scott, Robert Peach, Jeffrey H. Hager	18
12	BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90 2009 ·Molecular Cancer Therapeutics ·Karen Lundgren, Hong Zhang, (unknown), Nanni Huser, (unknown), (unknown), David J. Busch, Laura Neely, John Sensintaffar, (unknown), (unknown), Jessica Friedman, Robert H. Scannevin, Adeela Kamal, Kevin Hong, Srinivas Rao Kasibhatla, Marcus F. Boehm, Francis Burrows	140
13	BIIB021 is a small molecule inhibitor of the heat shock protein, Hsp90, that shows potent anti-tumor activity in preclinical models 2007 ·Karen Lundgren, Hong Zhang, Adeela Kamal, Rachel Lough, (unknown), John Sensintaffar, David J. Busch, Cindy Yang, Laura Neely, Samina Y. Khan, Kevin Hong, Srinivas Rao Kasibhatla, Marcus F. Boehm, Francis Burrows	3
14	CNF2024 - The first clinical stage synthetic oral Hsp90 inhibitor 2006 ·Cancer Research ·Karen Lundgren, Adeela Kamal, Rachel Lough, (unknown), John Sensintaffar, Cindy Yang, Hong Zhang, Gregg Timony, Kevin Hong, Srinivas Rao Kasibhatla, Marcus F. Boehm, Francis Burrows	1
15	A high-affinity conformation of Hsp90 confers tumor selectivity on Hsp90 inhibitors 2004 ·Cancer Research ·Adeela Kamal, John Sensintaffar, (unknown), Lin Zhang, Marcus F. Boehm, Lawrence C. Fritz, Francis Burrows	28
16	A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors breakdown → 2003 ·Nature ·Adeela Kamal, (unknown), John Sensintaffar, Lin Zhang, Marcus F. Boehm, Lawrence C. Fritz, Francis Burrows	1121
17	Tumor necrosis factor expression during mouse hepatitis virus-induced demyelinating encephalomyelitis 1995 ·Journal of Virology ·Stephen A. Stohlman, David R. Hinton, Daniel Cua, (unknown), John Sensintaffar, Florence M. Hofman, Stanley M. Tahara, Q. Y. Yao	39
18	Differential effects of flanking residues on presentation of epitopes from chimeric peptides 1994 ·Journal of Virology ·Cornelia C. Bergmann, Tong Lin, (unknown), John Sensintaffar, S. A. Stohlman	33
19	Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. 1990 ·PubMed ·Joanna M. Watson, John Sensintaffar, Jonathan S. Berek, Otoniel Martı́nez-Maza	207
20	Epithelial ovarian cancer cells constitutively produce interleukin-6 (IL6) 1990 ·Gynecologic Oncology ·Joanna M. Watson, John Sensintaffar, Reba M. Knox, Fumihiko Takatsuki, Otoniel Martı́nez-Maza, J. S. Berek	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact